| 1 |
Torres A, Niederman MS, Chastre J, et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociacion Latinoamericana del Tórax (ALAT)[J]. Eur Respir J, 2017, 50 (3): 1700582.
|
| 2 |
Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021[J]. Intensive Care Med, 2021, 47 (11): 1181-1247.
|
| 3 |
Lakbar I, Medam S, Ronflé R, et al. Association between mortality and highly antimicrobial-resistant bacteria in intensive care unit-acquired pneumonia[J]. Sci Rep, 2021, 11 (1): 16497.
|
| 4 |
Talbot GH, Das A, Cush S, et al. Evidence-based study design for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia[J]. J Infect Dis, 2019, 219 (10): 1536-1544.
|
| 5 |
Zaragoza R, Vidal-Cortés P, Aguilar G, et al. Update of the treatment of nosocomial pneumonia in the ICU[J]. Crit Care, 2020, 24 (1): 383.
|
| 6 |
Gideline Development Group. Adult patients with nosocomial pneumonia: epidemiology, diagnosis, and treatment[J]. Dtsch Arztebl Int, 2013, 110 (38): 634-640.
|
| 7 |
Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3)[J]. JAMA, 2016, 315 (8): 801-810.
|
| 8 |
Hamers L, Kox M, Pickkers P. Sepsis-induced immunoparalysis: mechanisms, markers, and treatment options[J]. Minerva Anestesiol, 2015, 81 (4): 426-439.
|
| 9 |
Fernando SM, Tran A, Cheng W, et al. Diagnosis of ventilator-associated pneumonia in critically ill adult patients—a systematic review and meta-analysis[J]. Intensive Care Med, 2020, 46 (6): 1170-1179.
|
| 10 |
Grousd JA, Rich HE, Alcorn JF. Host-pathogen interactions in gram-positive bacterial pneumonia[J]. Clin Microbiol Rev, 2019, 32 (3): e00107-18.
|
| 11 |
Jenkins A, Diep BA, Mai TT, et al. Differential expression and roles of Staphylococcus aureus virulence determinants during colonization and disease[J]. mBio, 2015, 6 (1): e02272-14.
|
| 12 |
Keane S, Martin-Loeches I. Host-pathogen interaction during mechanical ventilation: systemic or compartmentalized response?[J]. Crit Care, 2019, 23 (Suppl 1): 134.
|
| 13 |
Almansa R, Nogales L, Martín-Fernández M, et al. Transcriptomic depression of immunological synapse as a signature of ventilator-associated pneumonia[J]. Ann Transl Med, 2018, 6 (21): 415.
|
| 14 |
Quarton S, Livesey A, Pittaway H, et al. Clinical challenge of diagnosing non-ventilator hospital-acquired pneumonia and identifying causative pathogens: a narrative review[J]. J Hosp Infect, 2024, 149: 189-200.
|
| 15 |
Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society[J]. Clin Infect Dis, 2016, 63 (5): e61-e111.
|
| 16 |
Martin-Loeches I, Chastre J, Wunderink RG. Bronchoscopy for diagnosis of ventilator-associated pneumonia[J]. Intensive Care Med, 2023, 49 (1): 79-82.
|
| 17 |
Fagon JY, Chastre J, Wolff M, et al. Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia. A randomized trial[J]. Ann Intern Med, 2000, 132 (8): 621-630.
|
| 18 |
Pulido MR, Moreno-Martinez P, González-Galán V, et al. Application of BioFire FilmArray Blood Culture Identification panel for rapid identification of the causative agents of ventilator-associated pneumonia[J]. Clin Microbiol Infect, 2018, 24 (11): 1213.e1-1213.e4.
|
| 19 |
Martin-Loeches I, Dickson R, Torres A, et al. The importance of airway and lung microbiome in the critically ill[J]. Crit Care, 2020, 24 (1): 537.
|
| 20 |
杨瑾，刘雪克，张媛媛，等.肠道微生物来源石胆酸对脓毒症相关肝损伤的保护作用[J/OL].中华危重症医学杂志（电子版），2024，17（4）：265-274.
|
| 21 |
Navas-Molina JA, Peralta-Sánchez JM, González A, et al. Advancing our understanding of the human microbiome using QIIME[J]. Methods Enzymol, 2013, 531: 371-444.
|
| 22 |
Zhang Y, Ji P, Wang J, et al. RiboFR-Seq: a novel approach to linking 16S rRNA amplicon profiles to metagenomes[J]. Nucleic Acids Res, 2016, 44 (10): e99.
|
| 23 |
Langelier C, Kalantar KL, Moazed F, et al. Integrating host response and unbiased microbe detection for lower respiratory tract infection diagnosis in critically ill adults[J]. Proc Natl Acad Sci U S A, 2018, 115 (52): E12353-E12362.
|
| 24 |
刘艳波，陆远强.宏基因组二代测序技术在社区获得性肺炎患者病原学检测中的应用[J/OL].中华危重症医学杂志（电子版），2023，16（1）：20-27.
|
| 25 |
Song J, Liu S, Xie Y, et al. Diagnostic value of DNA or RNA-based metagenomic next-generation sequencing in lower respiratory tract infections[J]. Heliyon, 2024, 10 (9): e30712.
|
| 26 |
Quarton S, Livesey A, Jeff C, et al. Metagenomics in the diagnosis of pneumonia: protocol for a systematic review[J]. JMIR Res Protoc, 2024, 13: e57334.
|
| 27 |
Koncan R, Parisato M, Sakarikou C, et al. Direct identification of major Gram-negative pathogens in respiratory specimens by respiFISHR HAP Gram (-) Panel, a beacon-based FISH methodology[J]. Eur J Clin Microbiol Infect Dis, 2015, 34 (10): 2097-2102.
|
| 28 |
Alatawi AD, Hetta HF, Ali MAS, et al. Diagnostic innovations to combat antibiotic resistance in critical care: tools for targeted therapy and stewardship[J]. Diagnostics (Basel), 2025, 15 (17): 2244.
|
| 29 |
Su Y, Xiao Q, Ye S, et al. Metagenomic next-generation sequencing (mNGS) guides targeted antibiotic therapy and reduces mortality in sepsis: a propensity-matched retrospective cohort study[J]. BMC Infect Dis, 2025, 25 (1): 1430.
|
| 30 |
Xia Y, Ying Y, Wang S, et al. Effectiveness of lung ultrasonography for diagnosis of pneumonia in adults: a systematic review and meta-analysis[J]. J Thorac Dis, 2016, 8 (10): 2822-2831.
|
| 31 |
Staub LJ, Biscaro RRM, Maurici R. Emergence of alveolar consolidations in serial lung ultrasound and diagnosis of ventilator-associated pneumonia[J]. J Intensive Care Med, 2021, 36 (3): 304-312.
|
| 32 |
Xu E, Pérez-Torres D, Fragkou PC, et al. Nosocomial pneumonia in the era of multidrug-resistance: updates in diagnosis and management[J]. Microorganisms, 2021, 9 (3): 534.
|
| 33 |
Liapikou A, Cillóniz C, Torres A. Emerging strategies for the noninvasive diagnosis of nosocomial pneumonia[J]. Expert Rev Anti Infect Ther, 2019, 17 (7): 523-533.
|
| 34 |
Claessens YE, Debray MP, Tubach F, et al. Early chest computed tomography scan to assist diagnosis and guide treatment decision for suspected community-acquired pneumonia[J]. Am J Respir Crit Care Med, 2015, 192 (8): 974-982.
|
| 35 |
Upchurch CP, Grijalva CG, Wunderink RG, et al. Community-acquired pneumonia visualized on CT scans but not chest radiographs: pathogens, severity, and clinical outcomes[J]. Chest, 2018, 153 (3): 601-610.
|
| 36 |
Póvoa P, Martin-Loeches I, Ramirez P, et al. Biomarkers kinetics in the assessment of ventilator-associated pneumonia response to antibiotics — results from the BioVAP study[J]. J Crit Care, 2017, 41: 91-97.
|
| 37 |
Alessandri F, Pugliese F, Angeletti S, et al. Procalcitonin in the assessment of ventilator associated pneumonia: a systematic review[J]. Adv Exp Med Biol, 2021, 1323: 103-114.
|
| 38 |
Lisboa T, Seligman R, Diaz E, et al. C-reactive protein correlates with bacterial load and appropriate antibiotic therapy in suspected ventilator-associated pneumonia[J]. Crit Care Med, 2008, 36 (1): 166-171.
|
| 39 |
Giamarellos-Bourboulis EJ, Kotsaki A, Routsi C, et al. A prognostic score for the resolution of bacteremia by Gram-negative bacteria resistant to carbapenems[J]. Eur J Clin Microbiol Infect Dis, 2018, 37 (11): 2083-2089.
|
| 40 |
Xavier G, Melo-Silva CA, Santos CEVGD, et al. Accuracy of chest auscultation in detecting abnormal respiratory mechanics in the immediate postoperative period after cardiac surgery[J]. J Bras Pneumol, 2019, 45 (5): e20180032.
|
| 41 |
Chun K, Chung W, Kim AJ, et al. Association between acute kidney injury and serum procalcitonin levels and their diagnostic usefulness in critically ill patients[J]. Sci Rep, 2019, 9 (1): 4777.
|
| 42 |
Peng Y, Tao T, Yu NW, et al. Identification of circulating Tfh/Th subsets as a biomarker of developed hospital-acquired pneumonia[J]. Front Immunol, 2025, 16: 1513939.
|
| 43 |
Wang Z, Chang B, Zhang Y, et al. Clinical value of serum sTREM-1 and HBP levels in combination with traditional inflammatory markers in diagnosing hospital-acquired pneumonia in elderly[J]. BMC Infect Dis, 2022, 22 (1): 773.
|
| 44 |
Voza A, Aliberti S, Bonelli F, et al. A machine learning model including pentraxin-3 as predictor of outcomes in community-acquired pneumonia[J]. J Transl Med, 2025, 23 (1): 1205.
|
| 45 |
Esperatti M, Ferrer M, Giunta V, et al. Validation of predictors of adverse outcomes in hospital-acquired pneumonia in the ICU[J]. Crit Care Med, 2013, 41 (9): 2151-2161.
|
| 46 |
Martin-Loeches I, Shorr AF, Wunderink RG, et al. Outcomes in participants with ventilated nosocomial pneumonia and organ failure treated with ceftolozane/tazobactam versus meropenem: a subset analysis of the phase 3, randomized, controlled ASPECT-NP trial[J]. Ann Intensive Care, 2023, 13 (1): 8.
|
| 47 |
U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia: developing drugs for treatment guidance for industry[EB/OL]. (2020-06-01) [2025-09-25].
URL
|
| 48 |
European Medicines Agency. Addendum to the guideline on the evaluation of medicinal products indicated for treatment of bacterial infections[EB/OL]. (2013-10-24) [2025-09-25].
URL
|
| 49 |
Bussini L, Pascale R, Rinaldi M, et al. Diagnosis, management and treatment of nosocomial pneumonia in ICU: a narrative review[J]. J Emerg Crit Care Med, 2022, 6: 25-25.
|
| 50 |
Kim BG, Kang M, Lim J, et al. Comprehensive risk assessment for hospital-acquired pneumonia: sociodemographic, clinical, and hospital environmental factors associated with the incidence of hospital-acquired pneumonia[J]. BMC Pulm Med, 2022, 22 (1): 21.
|
| 51 |
Sopena N, Heras E, Casas I, et al. Risk factors for hospital-acquired pneumonia outside the intensive care unit: a case-control study[J]. Am J Infect Control, 2014, 42 (1): 38-42.
|
| 52 |
Liu Y, Di Y, Fu S. Risk factors for ventilator-associated pneumonia among patients undergoing major oncological surgery for head and neck cancer[J]. Front Med, 2017, 11 (2): 239-246.
|
| 53 |
Wang R, Zhang J, He M, et al. A novel risk score for predicting hospital acquired pneumonia in aneurysmal subarachnoid hemorrhage patients[J]. Int Immunopharmacol, 2022, 108: 108845.
|
| 54 |
Kachalov VN, Kuster SP, Balakrishna S, et al. Modifiable and nonmodifiable risk factors for non-ventilator-associated hospital-acquired pneumonia identified in a retrospective cohort study[J]. Clin Microbiol Infect, 2022, 28 (11): 1451-1457.
|
| 55 |
D'Agata EM, Mount DB, Thayer V, et al. Hospital-acquired infections among chronic hemodialysis patients[J]. Am J Kidney Dis, 2000, 35 (6): 1083-1088.
|
| 56 |
Kremer WM, Gairing SJ, Kaps L, et al. Characteristics of bacterial infections and prevalence of multidrug-resistant bacteria in hospitalized patients with liver cirrhosis in Germany[J]. Ann Hepatol, 2022, 27 (5): 100719.
|
| 57 |
Apostolopoulou E, Bakakos P, Katostaras T, et al. Incidence and risk factors for ventilator-associated pneumonia in 4 multidisciplinary intensive care units in Athens, Greece[J]. Respir Care, 2003, 48 (7): 681-688.
|
| 58 |
Adiga A, Grudzinska F, Dosanjh D, et al. S16 Prognostication in hospital acquired pneumonia—are current scoring systems fit for purpose?[J]. Thorax, 2021, 76 (Suppl 2): A14-A15.
|